Back
Compare AU
Compare DRUG vs. LEND
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the VanEck Glbl Listed Private Credit (Aud Hedged) ETF (LEND). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | LEND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 23 |
Median incremental investment | $745.07 | $1,125.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,592.71 | $6,127.45 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | LEND | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | LEND.AX was created on 2024-01-31 by VanEck. The fund's investment portfolio concentrates primarily on broad credit fixed income. The ETF currently has 215.3m in AUM and 26 holdings. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars. The Fund does not necessarily aim to perfectly replicate the Reference Index on a one-to-one basis. |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) | Main Street Capital Corp (7.93 %) Ares Capital Corp (7.72 %) Blackstone Secured Lending Fund Ordinary Shares (7.70 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | United States (100.00 %) |
Management fee | 0.57 % | 0.65 % |
Key Summary
DRUG | LEND | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.65 % |
Price | $8.54 | $14.35 |
Size | $176.152 million | $218.330 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 6.99 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 01/02/2024 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | LEND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 23 |
Median incremental investment | $745.07 | $1,125.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,592.71 | $6,127.45 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | LEND | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | LEND |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |